JP2023505233A - アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 - Google Patents

アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 Download PDF

Info

Publication number
JP2023505233A
JP2023505233A JP2022533468A JP2022533468A JP2023505233A JP 2023505233 A JP2023505233 A JP 2023505233A JP 2022533468 A JP2022533468 A JP 2022533468A JP 2022533468 A JP2022533468 A JP 2022533468A JP 2023505233 A JP2023505233 A JP 2023505233A
Authority
JP
Japan
Prior art keywords
subject
active agent
unit dosage
dosage form
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505233A5 (https=
Inventor
ジョン パトリック ジュニア ケイシー，
デイビッド アーサー ベリー，
ティモシー エフ． ブリッグス，
レナード バックビンダー，
ミ－ジョン キム，
アンナ リャン，
アヌシュヤ パンディアン，
Original Assignee
フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド filed Critical フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド
Publication of JP2023505233A publication Critical patent/JP2023505233A/ja
Publication of JP2023505233A5 publication Critical patent/JP2023505233A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022533468A 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法 Pending JP2023505233A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962944258P 2019-12-05 2019-12-05
US62/944,258 2019-12-05
US202063074770P 2020-09-04 2020-09-04
US63/074,770 2020-09-04
PCT/US2020/063307 WO2021113635A1 (en) 2019-12-05 2020-12-04 Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
JP2023505233A true JP2023505233A (ja) 2023-02-08
JP2023505233A5 JP2023505233A5 (https=) 2023-12-11

Family

ID=76221221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533468A Pending JP2023505233A (ja) 2019-12-05 2020-12-04 アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法

Country Status (6)

Country Link
US (1) US20220296555A1 (https=)
EP (1) EP4069208A4 (https=)
JP (1) JP2023505233A (https=)
AU (1) AU2020397933A1 (https=)
CA (1) CA3163526A1 (https=)
WO (1) WO2021113635A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135494A (ja) * 1997-07-18 1999-02-09 Biremo Sci:Kk 糖尿病又は腎不全に伴う合併症の診断試薬
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
JP2002524505A (ja) * 1998-09-15 2002-08-06 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 高血中脂質濃度に因る疾患の予防または治療のための、ケイ皮酸誘導体を含む組成物
JP2008506772A (ja) * 2004-07-19 2008-03-06 エヌ．ブイ．・ヌートリシア ケトン体の調節のために、アスパラギン酸塩およびビタミンｂ１２またはビオチンを使用するための製剤
JP2016216378A (ja) * 2015-05-15 2016-12-22 公立大学法人岡山県立大学 ウロリチン類を含有する抗糖化剤
JP2017171638A (ja) * 2016-03-25 2017-09-28 花王株式会社 骨強度改善剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101167802B (zh) * 2006-10-25 2011-04-20 中国科学院上海生命科学研究院 肉桂提取物的制备方法、肉桂提取物、其组合物以及用途
CA2737431C (en) * 2008-09-18 2016-03-29 Nippon Zoki Pharmaceutical Co., Ltd. Amino acid derivative

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135494A (ja) * 1997-07-18 1999-02-09 Biremo Sci:Kk 糖尿病又は腎不全に伴う合併症の診断試薬
JP2002524505A (ja) * 1998-09-15 2002-08-06 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 高血中脂質濃度に因る疾患の予防または治療のための、ケイ皮酸誘導体を含む組成物
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
JP2008506772A (ja) * 2004-07-19 2008-03-06 エヌ．ブイ．・ヌートリシア ケトン体の調節のために、アスパラギン酸塩およびビタミンｂ１２またはビオチンを使用するための製剤
JP2016216378A (ja) * 2015-05-15 2016-12-22 公立大学法人岡山県立大学 ウロリチン類を含有する抗糖化剤
JP2017171638A (ja) * 2016-03-25 2017-09-28 花王株式会社 骨強度改善剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
竹内正義 他: "生活習慣病の発症・進展におけるToxic AGEs (TAGE)の関与", 金医大誌, vol. 40, JPN7024005422, 2015, pages 95 - 103, ISSN: 0005650156 *
竹内正義: "生活習慣病におけるTAGE (toxic AGEs) 病因説", 北陸大学 紀要, vol. 第28号, JPN7024005423, 2004, pages 33 - 48, ISSN: 0005650155 *

Also Published As

Publication number Publication date
EP4069208A4 (en) 2024-01-10
CA3163526A1 (en) 2021-06-10
US20220296555A1 (en) 2022-09-22
WO2021113635A1 (en) 2021-06-10
AU2020397933A1 (en) 2022-06-30
EP4069208A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
JP7377220B2 (ja) 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法
US10662218B2 (en) Analogs of celastrol
US10676438B2 (en) KCNQ2-5 channel activator
EP2310392A2 (en) Tricyclic antagonists of prostaglandin d2 receptors
CA2873104A1 (en) Compositions and methods for the treatment of mucositis
JP2004522710A (ja) 性機能障害の治療
US9181248B2 (en) [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors
EP4470540A1 (en) Use of heterocyclic compound
RU2382029C2 (ru) Новые производные циклогексана
US20260001872A1 (en) Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof
WO2022092294A1 (ja) サルコペニア関連疾患等の新規治療および予防
US9102636B2 (en) Analgesic compounds, compositions, and uses thereof
JP2018009019A (ja) Ｋｃｎｑ２〜５チャネル関連疾患の予防および／または治療剤
TW202023535A (zh) Dp拮抗劑
EP1902054B1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
JP7498504B2 (ja) 脳神経または心臓保護剤としてのアミノチオール系化合物の使用
JP2023505233A (ja) アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法
JP2023504547A (ja) アシル化された活性薬剤並びに代謝異常及び非アルコール性脂肪性肝疾患の治療のためのそれらの使用の方法
TWI220650B (en) Treatment of sexual dysfunction
CN101351495A (zh) 脂肪酸酰胺水解酶抑制剂
RU2749188C2 (ru) Композиции и способы лечения желудочно-кишечных полипов
TW200526205A (en) Nitrogen-containing heterocyclic compound, and medicine containing such compound as effective ingredient
RU2776845C2 (ru) Аналоги целастрола
WO2007041506A1 (en) Purine formulations and methods for managing disorders
WO2014037832A2 (en) Compositions and methods for the treatment of epilepsy and neurological diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250728